Essex Bio-Technology Limited reported a share repurchase of 350,000 ordinary shares on 2 July 2026 through on-market transactions on the Hong Kong Stock Exchange, according to its latest Next Day Disclosure Return.

The repurchase was executed at prices ranging from HK$2.50 to HK$2.61 per share, translating into a volume-weighted average cost of HK$2.5586 per share and a total cash outlay of HK$0.90 million.

Key capital changes after the transaction: • Issued shares (excluding treasury shares) fell from 566.00 million to 565.65 million, a marginal decline of 0.06%. • Treasury shares increased from 1.01 million to 1.36 million. • Total issued shares remained unchanged at 567.01 million.

The repurchase forms part of the mandate approved on 26 May 2026, which authorises Essex Bio-Tech to buy back up to 56.70 million shares. Including the latest transaction, the company has repurchased 1.36 million shares under this mandate, representing approximately 0.24% of the shares outstanding on the mandate date.

All 350,000 shares acquired on 2 July 2026 were retained as treasury shares; no cancellations have occurred. In line with Hong Kong listing rules, Essex Bio-Tech is subject to a moratorium on new share issues or treasury share sales until 1 August 2026.